Theravance Inc.
901 Gateway Boulevard
South San Francisco,
CA 94080
United States - Map
Phone: 650-808-6000
Fax: 650-827-8690
Web Site: http://www.theravance.com
| Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. It offers Telavancin (cSSSI), a bactericidal injectable antibiotic for the treatment of complicated skin and skin structure infections; Telavancin (HAP) that is used to treat hospital-acquired pneumonia or nosocomial pneumonia; and Horizon to develop and commercialize long-acting beta2 agonist (LABA) product candidate as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long acting muscarinic antagonist (LAMA) for COPD. In addition, it offers GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound, which is in phase 2 clinical studies; and TD-5108, a gastrointestinal motility dysfunction program for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. The company has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compounds. The company also has a strategic alliance with GlaxoSmithKline plc. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance was founded in 1996 and is headquartered in South San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. P. Roy Vagelos M.D., 79
Co-Founder, Chairman and Member of Science & Technology Advisory Committee |
$
89.00K | N/A | Mr. Rick Winningham , 49
Chief Exec. Officer, Pres, Director, Member of Stock Option Committee and Member of Science & Technology Advisory Committee |
N/A
| N/A | Dr. George M. Whitesides Ph.D., 69
Co-Founder, Director, Member of Compensation Committee and Member of Science & Technology Advisory Committee |
$
41.00K | N/A | Mr. Michael W. Aguiar , 42
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
N/A
| N/A | Mr. Bradford J. Shafer , 48
Sr. VP, Sec. and Gen. Counsel |
$
482.00K |
$
942.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.10% Nasdaq 
0.27%
Profile
